Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
6.06 ^USD	-6.63%		-8.73%	-47.03%

05-22	Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing	MT
05-21	Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS	CI

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

May 09, 2024 at 07:09 am

Ironwood Pharmaceuticals, Inc. revised earnings guidance for its Fiscal Year 2024. Total Revenue reported its Prior 2024 Guidance of $435 to $455 million as compared to Revised 2024 Guidance of revenue to be $405 to $425 million.

Latest news about Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing	05-22	MT
Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS	05-21	CI
Sector Update: Health Care Stocks Higher Late Afternoon	05-09	MT
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	05-09	MT
Sector Update: Health Care	05-09	MT
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut	05-09	MT
Transcript : Ironwood Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M	05-09	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M	05-09	MT
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024	05-09	CI
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	03-28	CI
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	02-29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	02-29	MT
Top Premarket Decliners	02-29	MT
Transcript : Ironwood Pharmaceuticals, Inc. - Special Call	02-29
Ironwood says bowel disease treatment meets main goal in late-stage trial	02-29	RE
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating	02-16	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	02-15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	02-15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	02-15	MT
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	02-15	MT
Transcript : Ironwood Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	02-15	CI
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $435M - $455M	02-15	MT

Chart Ironwood Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.06 USD

Average target price

15.83 USD

Spread / Average Target

+161.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IRONWOOD PHARMACEUTICALS, INC.	-47.03%	1.03B
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research